Loading clinical trials...
Loading clinical trials...
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Conditions
Interventions
Biospecimen Collection
Computed Tomography
+4 more
Locations
886
United States
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Southern Cancer Center PC-Daphne
Daphne, Alabama, United States
Southern Cancer Center PC-Mobile
Mobile, Alabama, United States
Southern Cancer Center PC-Providence
Mobile, Alabama, United States
Southern Cancer Center PC-Springhill
Mobile, Alabama, United States
Katmai Oncology Group
Anchorage, Alaska, United States
Start Date
July 22, 2016
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
April 24, 2026
NCT01386385
NCT02503722
NCT00334815
NCT01413750
NCT00254384
NCT01912625
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions